News

A case of Lambert-Eaton myasthenic syndrome (LEMS) was identified in an older man who was initially hospitalized with a wrongful diagnosis of aspiration pneumonia. He was later diagnosed with small cell lung cancer (SCLC), an aggressive form of lung cancer that is often associated with LEMS, but was too…

A decision by the Federal Court of Appeal of Canada is restoring the availability of Ruzurgi (amifampridine) to treat children and adults with Lambert-Eaton Myasthenic Syndrome (LEMS) in that country, Medunik Canada announced. Specifically, the court returned for a second time the notice of compliance, or approval, …

Teva Pharmaceuticals is seeking authorization from federal regulators in the U.S. to produce and sell a generic version of Firdapse (amifampridine), an approved treatment for Lambert-Eaton myasthenic syndrome (LEMS). Firdapse, marketed by Catalyst Pharmaceuticals, was approved by the U.S. Food and Drug Administration in 2018 as the…

An elderly man in Japan is reported to have developed Lambert-Eaton myasthenic syndrome (LEMS) as a likely side effect of being treated with Tecentriq (atezolizumab) for a type of cancer called small cell lung cancer (SCLC). The report, “Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung…

Little evidence was found for a causal relationship between the use of an immune checkpoint inhibitor (ICI) for the treatment of cancer and the onset of Lambert-Eaton myasthenic syndrome (LEMS) or myasthenia gravis (MG), according to a new review study. Still, because most included data came from case…

While unhappy with shortcomings in the legislation, the National Organization for Rare Disorders (NORD) nonetheless is applauding a year-end U.S. spending package that included several programs and reforms crucial to those with rare diseases, including Lambert-Eaton myasthenic syndrome (LEMS). As part of an expansive $1.7 trillion package, signed…

Among those with Lambert-Eaton myasthenic syndrome (LEMS) and other forms of paraneoplastic neurological syndrome, younger patients often experience a longer delay between symptom onset and seeking medical attention — a delay that can result in worse clinical outcomes, a new study indicates. “Patients aged [65 years or younger]…

The National Organization for Rare Disorders (NORD) is requesting applications from patient advocacy organizations to host new or existing patient registries for rare disorders, such as Lambert-Eaton myasthenic syndrome, on its IAMRARE platform. To expand its collection of patient-reported data, which could lead to new treatments and…

People with small cell lung cancer (SCLC) treated with the immune-based cancer therapy atezolizumab are at an increased risk of developing Lambert-Eaton myasthenic syndrome (LEMS), according to a database analysis of adverse events. The analysis was detailed in a study, “Increased risk of Lambert-Eaton myasthenic syndrome (LEMS)…

A possible first case of a man with non-small cell lung cancer (NSCLC) developing Lambert-Eaton myasthenic syndrome (LEMS) after being treated with Tecentriq (atezolizumab) has been reported in Pennsylvania. This case adds to prior evidence linking the use of Tecentriq, as well as the immunotherapies Opdivo and…